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West Nile virus (WNV) was detected in the United 
States in 1999, has reoccurred every summer since, and 
has become endemic. Transfusion transmission was docu-
mented in 2002, and screening of blood donations for WNV 
began in 2003. We investigated genetic variation of WNV in 
human isolates obtained from specimens collected from 30 
infected blood donors who tested positive for WNV RNA dur-
ing 2002–2005. Complete genomic sequences of 8 isolates 
and structural gene sequences from 22 additional isolates 
were analyzed. We found some genetic diversity in isolates 
from different geographic regions and genetic divergence 
from reported sequences from epidemics in 1999–2001. 
Nucleotide divergence of structural genes showed a small 
increase from 2002 (0.18%) to 2005 (0.37%), suggesting 
absence of strong selective pressure and limited genetic 
evolution of WNV during that period. Nevertheless, WNV 
has continued to diverge from precursor isolates as geo-
graphic distribution of the virus has expanded.
W
est Nile virus (WNV) is a small, enveloped, posi-
tive-strand RNA virus of the genus Flavivirus and 
a member of the Japanese encephalitis serocomplex. The 
plus-sense RNA genome is ≈11 kb and contains a single 
open reading frame ﬂ  anked by 5′ and 3′ untranslated re-
gions (UTRs). The encoded polyprotein is processed into 
3 structural and 7 nonstructural (NS) proteins that are es-
sential for viral replication, assembly, and release. WNV is 
maintained in nature by transmission between mosquitoes 
and birds but can also infect humans and other mammals 
(1) and reptiles (2). Most human infections are asymptom-
atic (70%–80%); symptomatic cases range from ﬂ  ulike ill-
ness to severe neurologic disease (>1% of cases) (3–5).
The ﬁ  rst US outbreak of WNV occurred in 1999 in 
New York City; 68 human infections, mostly as meningo-
encephalitis, were conﬁ  rmed, resulting in 7 deaths. Since 
1999, WNV epidemics have reoccurred yearly with 23,975 
reported human cases of disease and 962 deaths through 
2006 (www.cdc.gov/ncidod/dvbid/westnile).
In 2002, the virus spread westward and the number of 
reported human cases increased dramatically. The North 
American epidemics of 2002 and 2003 represent the larg-
est WNV outbreaks ever reported (6). Additional modes 
of WNV transmission were identiﬁ  ed in 2002, including 
human-to-human transmissions from mother to child, or-
gan transplantation, and blood transfusion (7–9). The quick 
spread of the virus raised questions regarding viral adapta-
tion and prompted a detailed investigation of the genetic 
evolution of the virus.
The prototype WNV isolate, NY99-ﬂ  amingo382–99 
(WN-NY99; GenBank accession no. AF196835) was ob-
tained from a ﬂ  amingo infected during the 1999 outbreak 
in New York. This isolate belongs to lineage I and is most 
closely related to the Israel-98 goose isolate AF481864 (IS-
98) (6,10). Phylogenetic comparisons of partial and com-
plete nucleotide sequences from US isolates collected be-
tween the 1999 and 2000 epidemics with WN-NY99 isolate 
showed a high degree of genetic similarity with >99.8% 
nucleotide homology and >99.9% amino acid homology 
(11–14). A study of 22 different WNV isolates from 2001 
and 2002 showed genetic variation of 0.35% (mean 0.18%) 
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in the premembrane (preM) and envelope (env) genes com-
pared with WN-NY99 (15).
Subsequently, 2 distinct genotypes were detected in 
strains obtained from Texas in 2002 (15). One new genet-
ic variant widely spread over the United States diverged 
from the original WN-NY99 strain by several conserved 
nucleotide mutations and 1 aa substitution in the env pro-
tein. Recent studies have highlighted the emergence of a 
new WNV dominant genotype, named WN02, which has 
been increasingly prevalent in the United States since 2002 
(16–19). Although 13 nt mutations became ﬁ  xed in the new 
dominant genotype compared with the WN-NY99 proto-
type, the highest nucleotide sequence divergence of WNV 
strains isolated after 2002 is still in the range of 0.4%–0.5% 
(18,20). The reason for displacement of the WN-NY99 
genotype by a new dominant genotype in North America 
is not clear, but could have been caused by differences in 
transmission efﬁ  ciency of domestic mosquitoes that may 
offer a selective advantage for the newly emerged genotype 
(20,21).
Several studies on the genetic variation of WNV have 
been published (12,15,17,19,21,22). However, continu-
ous monitoring of variability is needed because sensitiv-
ity of blood donor screening and diagnostic assays may 
be affected, producing a negative effect on public health. 
Genetic variability could also affect viral pathogenesis, 
development of vaccines, and development of efﬁ  cacious 
therapeutic agents.
This study reports the genomic variation of WNV 
observed in clinical isolates obtained in the continental 
United States during 4 consecutive years (2002–2005). 
We observed an increase in the number of mutations in 
the full WNV genome from 0.18% in 2002 to 0.37% in 
2005. It should be noted that 80% of the nucleotide changes 
in structural regions are transitions (T ↔ C) and 75% are 
silent mutations. Thus, WNV has continued to slowly di-




This study included 30 plasma specimens (Table 1) 
obtained from blood donor units positive for WNV by 
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Table 1. Sequences of 30 West Nile virus isolates from the United States* 
Isolate ID  Year  Geographic location  No. passages in Vero cells†  GenBank accession no. 
FDA/HU-02 2002 NY 3 AY646354 
ARC10–02 2002 MI 1 AY795965 
ARC12–02 2002 OH 1 DQ666453 
ARC13–02 2002 MI 1 DQ666454 
ARC15–02 2002 MI 1 DQ666455 
ARC16–02 2002 IN 1 DQ666456 
ARC17–02 2002 GA 1 DQ666457 
BSL5–03 2003 UT 1 DQ005530 
BSL9–03 2003 TX 1 DQ666458 
BSL56–03 2003 ND 1 DQ666459 
BSL62–03 2003 SD 2 DQ666460 
BSL114–03 2003 TX 2 DQ666461 
RMS1–03 2003 MN 1 DQ666462 
RMS2–03 2003 IN 1 DQ666463 
RMS3–03 2003 IN 1 DQ666464 
RMS4–03 2003 IA 1 DQ666465 
BSL1–04 2004 AZ 1 DQ666466 
BSL2–04 2004 AZ 1 DQ666467 
BSL4–04 2004 AZ 2 DQ666468 
BSL5–04 2004 AZ 1 DQ666448 
BSL6–04 2004 AZ 1 DQ666469 
BSL7–04 2004 AZ 2 DQ666470 
BSL8–04 2004 AZ 2 DQ666471 
GCTX1 2005 TX 1 DQ666449 
GCTX2 2005 TX 1 DQ666450 
BSL2–05 2005 SD 1 DQ666452 
BSL6–05 2005 AZ 1 DQ666472 
BSL9–05 2005 TX 1 DQ666473 
BSL10–05 2005 LA 1 DQ666474 
BSL13–05 2005 AZ 1 DQ666451 
*Isolates in boldface have been completely sequenced.  
†Indicates passage of viral isolate from which RNA extracts were used to obtain the genomic sequence. RESEARCH
nucleic acid tests used to screen blood donations under 
Food and Drug Administration (FDA)–approved nation-
wide clinical trials; the specimens were collected in 13 
states in the continental United States. All samples were 
collected under Institutional Review Board–approved in-
formed consent provided by each of the institutions per-
forming donor screening.
Virus Isolation in Vero Cells
Vero cells were plated in T75 ﬂ  asks and grown to 85% 
conﬂ  uence in Eagle minimal essential medium (GIBCO 
BRL, Gaithersburg, MD, USA) containing 5% fetal bo-
vine serum (Hyclone, Logan, UT, USA) and 10 μg/mL of 
penicillin/streptomycin (GIBCO-BRL). For viral isolation, 
medium was removed, and 500 μL of each plasma sample 
was added to individual ﬂ  asks and the volume was adjusted 
to 5 mL with fresh medium. Cultures were incubated for 
2 hours with the plasma, either at room temperature with 
gentle rocking or at 37°C with sporadic mixing. A total of 
10 mL of fresh medium was then added and cultures were 
incubated at 37°C in an atmosphere of 5% CO2. Cultures 
were observed daily for cytopathic effect under phase mi-
croscopy. Supernatants were harvested when an extensive 
cytopathic effect was observed, centrifuged to remove cell 
debris, and frozen at –70°C until further analysis.
RNA Extraction, Reverse Transcription, and PCR
RNA extracts were obtained from 1-mL plasma sam-
ples by using Trizol reagent (Invitrogen, Carlsbad, CA, 
USA), and extracts were resuspended in 20 μL of water. 
RNA samples from viral passages were isolated from 140 
μL of culture supernatants by using the QiaAMP viral RNA 
extraction kit (QIAGEN, Valencia, CA, USA) according 
to the manufacturer’s protocol. RNA extracts were stored 
at –70°C until further analysis. Reverse transcription reac-
tions were performed in a ﬁ  nal volume of 20 μL that con-
tained 10 μL of RNA and speciﬁ  c WNV reverse primers by 
using SuperScript III (Invitrogen) according to the manu-
facturer’s instructions. Speciﬁ  c primers used for both PCR 
ampliﬁ  cation and sequencing were designed according to 
available sequence information in GenBank and based on 
alignments of published WNV sequences. PCR ampliﬁ  ca-
tion of overlapping fragments to cover the complete vi-
ral genome was performed by using 15 pairs of primers 
(Table 2). Partial sequences for the structural region were 
obtained by using primer sets 1, 2, and 3. cDNA specimens 
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Table 2. Primer sets used for PCR analyses of West Nile virus and sizes of overlapping amplicons*  
Set/location  Amplicon size, kb  Name  Sequence (5ƍ ĺ 3ƍ) 
F1  AGTAGTTCGCCTGTGTGAGCTGAC  1/F1–R1300 1.3 
R1300  TTGGCGCATGTGTCAATGCT 
F980  CTTGGAATGAGCAACAGAGA  2/F980–R2000 1.0 
R2000  GTTAGGTCGTTCAATGAAGC 
F1690  GAGACGTTAATGGAGTTTGA  3/F1690–R2685 1.0 
R2670  CTTCACTGCTTCCCACATTTG 
F2340  TTCGGAGGCATGTCCTGGAT  4/F2340–R3420 1.1 
R3420  CTGATCTCCATACCATACCAACA 
F3330  GAGAGCTGCGGACACCGTGGACC  5/F3330–R4120 0.8 
R4120  CATAGCAGACTTGCTCCTTTCT 
F4070  CTGTTGATGGTCGGAATAGG  6/F4070–R4950 0.9 
R4950  CCTGGTTTCGTCTGGACGTT 
F4810  CGCCTGGACCCATACTGG  7/F4810–R5650 0.85 
R5650  CCATTCGTATCCAGAGTTCCA 
F5510  AGCATTGCAGCAAGAGGTTA  8/F5510–R6430 0.9 
R6430  TAGTGCCTGGTGATCCGAGTACAC 
F6290  CGACCGGAGGTGGTGCTTTGATGG  9/F6290–R6770 0.5 
R6770  CCTGGAACTTCAGCCATCCA 
F6690  CCTCCTCATGCAGCGGAA  10/F6690–R7550 0.85 
R7550  GAGCTTGCTCCATTCTCCCA 
F7420  CCACACCCATCATGCAGAA  11/F7420–R8260 0.85 
R8260  CGTTGGAGCAGCTCCATCTT 
F8170  CATAGGACGATTCGGGTCCT  12/F8170–R9050 0.9 
R9050  CTCTTTCCCATCATGTTGTAAATGC 
F8920  CAGCTTTGGGTGCCATGTT  13/F8920–R9810 0.9 
R9810  GAACCTGCTGCCAATCATACC 
F9750  TCCTCAATGCTATGTCAAAGGT  14/F9750–R10630 0.9 
R10630  GGTCCTCCTTCCGAGACGGT 
F10550  TGAGTAGACGGTGCTGCCTG  15/F10550–R11029 0.5 
R11029  GATCCTGTGTTCTCGCACCACCAG 
*Internal sequencing primers were also used and their sequences are available upon request. Genetic Variability of West Nile Virus
were ampliﬁ  ed by using the Hi-Fidelity PCR system (Invit-
rogen) according to the manufacturer’s instructions.
DNA Sequencing
PCR products were puriﬁ  ed by agarose gel electropho-
resis by using the MinElute Gel Extraction Kit (QIAGEN) 
according to the manufacturer’s protocol. Both strands 
were subjected to direct sequencing by using amplifying 
primers (Table 2) and additional internal sequence prim-
ers. Sequencing reactions were performed by using the ABI 
PRISM BigDye Terminator version 3.1 Cycle Sequencing 
Kit (Applied Biosystems, Foster City, CA, USA) according 
to the manufacturer’s protocol and analysis by using the 
ABI Prism 3100 system (Applied Biosystems).
Sequence Analysis
Sequencing data were assembled and analyzed by us-
ing the Vector NTI Advance 10 software package (Invitro-
gen). Nucleotide and deduced amino acid sequences from 
each isolate were aligned by using the Align X program in 
Vector NTI and compared with prototype WN-NY99 and 
previously published sequences of isolates from different 
regions of the United States and other countries. Phyloge-
netic relationship studies were based on several methods of 
analysis (distance, parsimony, and likelihood algorithms) 
by using MEGA version 3.1 (www.megasoftware.com). 
All studied isolates were compared with each other, and 
phylogenetic trees were constructed by using the Kimura 
2-parameter method that included transitions and transver-
sions to show genetic relationships of isolates in this study 
with other WNV isolates in GenBank.
Results
Because of limited volume of plasma specimens avail-
able, viruses were isolated from Vero cell cultures for 
sequence analysis. We assessed the potential of the viral 
isolation procedure to cause mutations in the viral genome 
by comparison of sequences of the structural region of 6 
specimens and their respective isolates after 3 passages in 
Vero cells. There were no changes in the RNA sequences 
obtained in each original plasma sample and the RNA se-
quences obtained in each of the passages in culture.
We investigated the genetic variability of 30 WNV 
isolates collected from plasma specimens from nucleic acid 
ampliﬁ  cation testing–positive blood donors in 13 states dur-
ing 2002–2005 (Table 1). Isolates were generated by cul-
tivation in Vero cells. The fragment that encompasses the 
5′-UTR, all structural genes, and part of NS1 (bp 1–2,685) 
from all 30 specimens were subjected to genomic sequenc-
ing. Eight of 30 isolates were fully sequenced.
The Appendix Table (online Appendix Table, avail-
able from www.cdc.gov/EID/content/14/3/436-appT.htm) 
compares conserved nucleotide mutations and deduced 
amino acid substitutions identiﬁ   ed in structural regions 
of all 30 isolates with the WN-NY99 isolate (AF196835). 
Approximately 80% of the nucleotide changes in structur-
al regions were transitions (T ↔ C) and 75% were silent 
mutations. All mutations in the preM and membrane (M) 
regions were silent, and 16 isolates shared the transition 
660 C → T. Several WNV strains from Europe and Asia, as 
well as Kunjin virus isolates, also had T at position 660, but 
both the prototype WN-NY99 and the IS-98 (AF481864) 
isolates contain 660 C. Twenty-nine of 30 isolates shared 2 
conserved nucleotide mutations in the env gene: 1442 T → 
C (Val 159 → Ala) and 2466 C → T that differentiates the 
new dominant genotype, WN02, from the preceding geno-
type WN99.
Construction of a phylogenetic tree by the maximum 
parsimony method (Figure 1) showed the degree of diver-
gence of isolates from WN-NY99. The average nucleotide 
divergence for structural genes has increased from 0.18% 
in 2002 to 0.37% in 2005.
The env protein has several biologic roles, which 
include viral entry, virion assembly and release, aggluti-
nation of erythrocytes, and induction of B- and T-cell re-
sponses that are associated with protective immunity. Thus, 
this protein may be involved in WNV evolution. The phy-
logenetic tree shown in Figure 2 was constructed by maxi-
mum parsimony analysis with env gene sequences from 
US isolates from 1999–2006 in GenBank and sequences of 
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Figure 1. Phylogenetic analyses based on maximum parsimony 
comparing the 2,685-bp nucleotide sequence, including the 
complete structural and the 5′-untranslated region of prototype West 
Nile virus (WNV) strain WN-NY99 with 30 WNV isolates collected 
during the 2002–2005 epidemics in the United States. Values in 
parentheses show percentage of nucleotide sequence divergence 
from WN-NY99. Scale bar represents a 1-nt change.RESEARCH
human isolates in our study. The isolates clustered in 2 
clades correlated with the parsimony-revealing mutation 
sites at positions 1442 and 2466.
Although preM, M, and env sequences show adequate 
phylogenetic representation, we also analyzed 8 complete 
genomes of WNV isolates for stronger evidence of evo-
lutionary relationships between isolates and additional 
mutations that may have implications in phenotypic prop-
erties of these isolates. Nucleotide changes and deduced 
amino acid substitutions of complete genomic sequences 
from 8 isolates are shown in Tables 3 and 4, respectively. 
When compared with WN-NY99 sequences, these se-
quences showed an increased number of nucleotide muta-
tions. FDA/Hu-02 isolated in 2002 showed 20 nt muta-
tions plus 1 insertion at position 10497, and 5 mutations 
resulted in amino acid substitutions on the basis of de-
duced sequence of viral polyprotein. ARC10–02 isolated 
in 2002 had 22 mutations, 3 of which resulted in amino 
acid substitutions. These 2 isolates showed ≈0.2% nucleo-
tide divergence.
The 2003 isolate BSL5–03 showed 39 mutations (nu-
cleotide divergence 0.35%), 7 of which were associated 
with predicted amino acid substitutions. These 3 isolates 
from 2002 and 2003 had 11 common mutations: 2 were in 
env (1442 T → C resulting in Val 449 → Ala and 2466 C 
→ T, a silent mutation); 8 were in the NS regions (4146 A 
→ G in NS2A; 2 C → T transitions at positions 4803 and 
6138 in NS3; 6996C → T and 7015T → C in NS4B; T → 
C transitions at positions 7938 and 8811 and 9352 C → T 
at NS5); and 1 in the 3-′UTR (10851 A → G).
The 2004 isolate BSL5–04 had 42 mutations with 7 
aa substitutions. The isolates from 2005 were as follows: 
GCTX1-05 had 56 mutations with 17 aa substitutions; 
GCTX2-05 had 41 mutations with 3 aa substitutions; 
BSL2–05 had 44 mutations with 10 aa substitutions plus 
a deletion of 14 nt (10480 to 10493) in the 3′-UTR; and 
BSL13–05 had 48 mutations with 8 aa substitutions. Iso-
lates from 2004 and 2005 shared a nucleotide mutation 
6721 G → A, which resulted in amino acid substitution 
Ala2209Thr in the NS4A. Four isolates from 3 consecutive 
years (BSL5–03 from 2003, BSL5–04 from 2004, GCTX1 
and BSL13–05 from 2005), shared an amino acid substi-
tution (Lys2842Arg) in NS5. Three isolates from 2005 
(GCTX1–05, BSL2–05 and BSL13–05) plus 1 isolate from 
2004 (BSL5–04) also shared a silent mutation at position 
8550 C → T.
The overall nucleotide divergence from the WN-
NY99 isolates from 2003, 2004, and 2005 showed a steady 
but small increase (BSL5–03, 035%; BSL5–04, 0.38%; 
BSL2–05, 0.39%; BSL13–05, 0.43%; GCTX1–05, 0.5%; 
and GCTX2–05, 0.37%). These ﬁ  ndings suggest relative 
stasis in WNV divergence. The 8 completely sequenced 
isolates shared conserved nucleotide mutations in the 
preM, M, env, NS2A, NS3, NS4B, and NS5 genes and the 
3′-UTR (Table 4). The largest number of conserved muta-
tions was in the NS3 and NS5 genes. No conserved muta-
tions were observed in the core, M, NS1, and NS2B genes 
or the 5′-UTR.
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Figure 2. Distance analysis of envelope glycoprotein of West Nile 
virus isolates collected during 1999–2006 epidemics in the United 
States. Phylogram is based on maximum parsimony analysis of 
complete nucleotide sequences of the envelope gene. Diamonds 
indicate isolates from this study. All isolates from clade 2 (WN02 
strain) contained conserved mutations at positions 1442 (T → C) 
and 2466 (C → T). Values near branches represent percentage 
support by parsimony bootstrap analysis. Scale bar represents a 
1-nt change. Genetic Variability of West Nile Virus
Discussion
Our study describes genetic variability observed 
among 30 clinical isolates of WNV from 13 states in the 
United States obtained during 2002–2005. Since the initial 
recognition of WNV in North America in 1999 (10), the 
virus has spread from the East to the West Coast and has 
become endemic. Genetic studies have shown that >50% of 
all WNV isolates in 2002 and >80% of all isolates in 2003 
had a new genotype that emerged in the United States in 
2001. The new dominant genotype (WN02) was character-
ized by 2 conserved nucleotide mutations in env (1442 T → 
C and 2466 C → T) and 1 deduced amino acid substitution 
(Val 159 → Ala) in the env protein (16–18). Displacement 
of the initial genotype (WN99) by WN02 has been attrib-
uted to differences in efﬁ  ciency of transmission of the virus 
by domestic mosquitoes (21). Genetic studies conducted 
during the early years of WNV activity in the United States 
identiﬁ  ed a small number of mutations and showed no 
changes suggesting speciﬁ  c adaptations (6,12,15). After 
the genetic shift in 2001–2002, most nucleotide changes 
observed were silent transitions (T ↔ C and A ↔ G). Lim-
ited variability in structural genes observed by our group 
and others (15,16,18,20,22) suggests the absence of strong 
immune selective pressure, which led to limited evolution 
of WNV during 2002–2005. Data in this report show that 
WNV has continued to diverge from precursor isolates as 
geographic distribution of the virus expanded.
On the basis of nucleotide sequences, 6 aa substitutions 
were predicted in the core protein of 5 isolates. Two ami-
no acid substitutions, Ser 11 → Asn in isolate BSL13–05 
and Met 21 → Thr in isolate FDA-Hu2002, were located 
within the core hydrophilic region outside α helices. The 
other amino acid substitutions (Met 34 → Val in isolate 
BSL06–04, Ala 52 → Val in isolate FDA-Hu2002, Ala 77 
→ Val in isolate ARC16–02, and Lys 79 → Arg in isolate 
BSL10–05) were located within α1, α2, α3, and α4 helices, 
respectively (23) and were not expected to affect confor-
mation, function, or antigenic properties of core protein.
Studies of WNV evolution have focused on the env 
protein because it plays a major role in immune response to 
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Table 3. Deduced amino acid substitutions in 8 completely sequenced West Nile virus isolates compared with isolate WN-NY99* 
Residue no. 
Nucleocapsid Envelope glycoprotein NS1
Isolate 11 21 52 294 298 342 449 472 529 602 663 684 799 895
WN-NY99  Ser Met Ala Leu Asn Asn Val Glu Leu Leu Ile Asn Ile Leu
FDA/HU-02  Thr Val Ala Ser
ARC10–02 Ala 
BSL5–03 Ala Val Val
BSL5–04 Ala 
GCTX1–05  Ser Ala
GCTX2–05  Ala Phe 
BSL2–05 Ser Ser Ala Gly Ile
BSL13–05 Asn Pro Ala Phe
Protein NS2A NS2B NS3 NS4A NS4B
Residue no.  1169 1438 1611 1688 1690 1702 1971 1991 2188 2193 2209 2213 2261 2301
WN-NY99  Lys Ser Val Met Arg Gly  Pro Phe Thr Phe Ala Val Leu Ser
FDA/HU-02  Gly 
ARC10–02 Ala 
BSL5–03 Arg Ser 
BSL5–04 Asn Ser Thr





Isolate 2488 2549 2755 2788 2820 2826 2842 3056 3104 3132 3191 3238 3240
WN-NY99  Ser Lys  Gly Asn Ser Glu Lys Pro Arg Arg Met Gln Pro Total
FDA/HU-02  5 
ARC10–02 Gly 3 
BSL5–03 Arg 6 
BSL5–04 Ser Arg Lys Gln 8
GCTX1–05  Arg Ser Leu Arg Cys Ser Thr 16
GCTX2–05  Ser 3 
BSL2–05 Gly Arg Gln 10
BSL13–05 Gly Arg Gln 8
*NS, nonstructural. RESEARCH
infection and immunologic pressure could lead to its varia-
tion (12,15–21,24,25). A total of 29 of 30 isolates in this 
study contained 2 conserved nucleotide mutations in env 
(1442 T → C and 2466 C → T) that differentiate the domi-
nant genotype from other genotypes and place these iso-
lates in the WN02 clade relative to WN-NY99 (Figure 2). 
The mutation 2466 C → T was a silent mutation. Mutation 
1442 T → C leads to the amino acid substitution Val 159 
→ Ala, located in the variable region close to the glycosyl-
ation site. Glycosylation of env protein can inﬂ  uence virus 
infectivity and has been considered a potential determinant 
of virulence in a mouse model (26–28).
All 7 isolates from 2004 were from Arizona and had 
2 common silent mutations in env: 1320 A → G present 
in all isolates, and 1974 C → T, present in 6 of 7 isolates. 
Mutation 1320 A → G is also present in reported attenu-
ated strains of WNV (AY532665, AY688948, M12294) 
(29) and was also reported in human isolate DQ164201 
from Arizona in 2004 and in the red-tailed hawk isolate 
DQ164204 from Colorado in 2003 (18). Mutation 1974 C 
→ T, found in isolates from Arizona and Texas, was detect-
ed in 2000 in New York (AF404756), which indicated that 
this mutation occurred at least twice. A Kunjin virus iso-
late from 2003 (AY274505) and isolate EthAn4766 from 
Ethiopia (AY603654) also had that mutation.
Phylogenetic analysis of complete genomes of WNV 
isolates provided stronger evidence of evolutionary rela-
tionships between isolates. Eight fully sequenced isolates 
were compared by phylogenetic analysis with 39 published 
complete WNV genomes present in the United States dur-
ing epidemics in 1999–2005 (Figure 3). The phylogenetic 
tree was constructed by maximum parsimony analyses and 
rooted by using WN-NY99 and IS-98; it clearly shows that 
these 2 isolates were the predecessors of other US WNV 
isolates. Analysis of nucleotide sequence alignment of 
complete WNV genomes indicated that most mutations 
that occur each year were not ﬁ  xed. However, WNV has 
continued to diverge and the total number of ﬁ  xed muta-
tions and the overall nucleotide divergence have increased. 
Some mutations in US isolates may have appeared as a re-
sult of native adaptation and genetic drift of parental WNV 
isolates (18).
Within the WN02 genotype, a sequence from NY 
2003 (DQ164189) formed 2 outgroups with moderately 
strong (96%) bootstrap support (Figure 3). Five of 8 iso-
lates in outgroup 2a were from Arizona and had the 6721 
G → A mutation resulting in amino acid substitution Ala 
209 → Thr. This mutation was already present in the 2003 
magpie isolate DQ164203 from Colorado and in the 2004 
human isolate DQ164201 from Arizona (18). These iso-
lates also shared silent mutation 8550 C → T, which had 
been reported in the 2004 human isolate DQ164201 from 
Arizona (18).
Local concentration of closely related isolates in Ar-
izona (Figures 2, 3) or in California (outgroup 1; Figure 
3) may have been caused by introduction of 1 or few ge-
netically similar viruses in the area with rapid spread to 
mosquitoes and local birds, which ampliﬁ  ed the original 
genome. Human infections in that area would therefore 
result from 1 or a few local WNV-colonizing genotypes 
and reﬂ  ect stochastic introduction of 1 or a few infected 
vectors, followed by rapid localized ampliﬁ  cation (19). In 
contrast, a larger number of different viruses were intro-
duced in other areas, as observed in Texas, which lead to a 
broader diversity of variants.
Several studies showed that mutations in conserved 
structures within the 3′-UTR did not affect WNV transla-
tion but could affect RNA replication and interaction be-
tween cellular protein eEF1A and WNV 3′-UTR, facilitat-
ing viral minus-strand synthesis (30–32). Isolate BSL2–05 
from South Dakota had a 14-nt deletion (10480–10493) 
and isolate FDA/Hu-02 had 1-nt insertion at position 
10497 in the 3′-UTR; the second isolate had larger plaques 
than WN-NY99. The recently published 2004 human iso-
late DQ431705 from North Dakota (19) had a 5-nt dele-
tion (10434–10439) in the same 3′-UTR variable region. 
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Table 4. Nucleotide mutations conserved in fully sequenced West Nile virus isolates from 2002–2005 epidemics in the United States 
compared with isolate WN-NY99* 
Gene or region 
preM Env NS2A NS3 NS4A NS4B NS5 3ƍ-UTR
Nucleotide no. 
Isolate 
660  1442 2466 4146 4803 6138 6238 6426 6721 6996 7015 7938 8621 8811 9352 10851 
WN-NY99  C T C A C C C C G C T T A T C  A 
FDA/HU-02  C  T  G  T  T      T  C  C  C  T G 
ARC10  2002   C  T  G  T  T  T  T  C  C  C  T G 
BSL5  2003 T  C  T  G  T  T  T  T  C  C  G  C  T G 
BSL5  2004  T C T G T T T T A T C C G C T  G 
GCTX1  2005  T C T G T T T T A T C C G C T  G 
GCTX2  2005  T C T G T T T T    T C C    C T  G 
BSL2  2005  T C T G T T T T A T C C    C T  G 
BSL13  2005  T C T G T T T T A T C C G C T  G 
*preM, premembrane; Env, envelope; NS, nonstructural; UTR, untranslated region. Genetic Variability of West Nile Virus
Previous studies had reported low genetic variation among 
WNV isolates in North America and emphasized a low fre-
quency of nucleotide variants in the 3′-UTR. Subsequent 
observations showed that nucleotide changes in the 3′-UTR 
played a role in rapid spread of this virus in the New World 
because nucleotide changes in the 3′-UTR had co-evolved 
with amino acid changes and affected interactions of heli-
case and RNA polymerase with their RNA substrate (33). 
Mutations in 3′-UTR appear to play a role in production 
of small-plaque temperature-sensitive variants or mouse-
attenuated phenotype variants (34).
Our study showed limited but continuous genetic vari-
ability with amino acid substitutions in WNV strains. We 
also found insertions and deletions in the 3′-UTR region 
that should be studied for assessment of their functional 
role. Phylogenetic studies of WNV isolates are needed to 
monitor microevolution of WNV that may affect patho-
genic properties of the virus and to assess the effectiveness 
of available commercial donor screening and diagnostic as-
says for detection of variant strains. Study of genetic vari-
ability may also provide insights into the development of 
vaccines and therapeutic agents.
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